MacroGenics, Inc.
MGNX
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who haveā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.60
Price-1.54%
-$0.02
1Y
Price
Market Cap
$100.897m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+30.1%
EBITDA Margin+23.1%
Net Profit Margin-42.0%
Free Cash Flow MarginRevenue
$126.002m
-15.1%
1y CAGR+27.5%
3y CAGR+45.2%
5y CAGREarnings
-$75.886m
-13.3%
1y CAGR-186.7%
3y CAGR-129.9%
5y CAGREPS
-$1.20
-12.1%
1y CAGR-177.7%
3y CAGR-123.6%
5y CAGRBook Value
$67.001m
$270.763m
Assets$203.762m
Liabilities$37.009m
DebtDebt to Assets
13.7%
-0.6x
Debt to EBITDAFree Cash Flow
-$164.758m
-128.6%
1y CAGR-35.7%
3y CAGR-16.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company